A measles vaccine for routine use should provide effective protection without producing undesirable reactions such as high fever, rash or involvement of the central nervous system. Live measles vaccine developed by Enders produces excellent antibody response and protection in humans but causes clinical reactions in most of those vaccinated (Enders, 1960) . These reactions can be reduced, but not eliminated, by the simultaneous injection of gamma-globulin with the vaccine. Recently, several further-attenuated measles vaccines have been developed, and the results of preliminary studies on these vaccines have been veryencouraging (Andelman et al., 1963; Hendrickse et al., 1964) . The WHO Scientific Group on Measles Vaccine Studies, whose report was published in 1963, recommended in July of that year that the World Health Organization should stimulate, co-ordinate and support a series of field trials on the further-attenuated measles vaccines in a number of countries with different climates. The present paper describes the results of one of these trials, which was carried out in Canada in 1964.
METHODS AND MATERIALS PLAN OF STUDY
The study was carried out in healthy infants and young children in an orphanage at Quebec City. The first part of the study was undertaken in March and April 1964 (spring trial) , and the second part in September and October 1964 (fall trial).
Spring trial
In all, 193 children, 8-33 months of age, were chosen for vaccination. The children were divided at random into five groups. Group I received Enders Edmonston B vaccine with gamma-globulin, Group II received Schwarz further-attenuated vaccine, Group mI was given Enders Edmonston B alone, Group IV received a placebo and Group V received Beckenham 20 further-attenuated vaccine.
Fall trial
Altogether 165 children, 7-27 months of age, were chosen for vaccination. The children were divided at random into four groups. Group I received Enders Edmonston B vaccine alone, Group It the Schwarz vaccine, Group III Enders Edmonston B plus gamma-globulin and Group IV a placebo injection. In addition to these groups, a group of 29 infants 6 months old received Schwarz vaccine. Beckenham 20 vaccine free of avian leucosis virus was not available for this trial.
In both trials the children were bled one week before and one month after vaccination. Of the 193 children vaccinated in the spring trial 7 had prevaccination antibodies to measles virus. Of the 165 children vaccinated in the fall trial 6 had prevaccination antibodies. The postvaccination sera of these children showed no increase in antimeasles titres and the children were excluded from both studies. To 
SERUM ANTIBODY TITRATIONS
Prevaccination and postvaccination sera were simultaneously titrated using the haemagglutinationinhibition (HI) and serum-neutralization tests. The HI test was performed by Rosen's method (Rosen, 1961) adapted to Takatsy's micro-technique (Takatsy, 1955; Sever, 1962) . Since none of the 400 prevaccination sera tested contained non-specific haemagglutination inhibitors, the kaolin treatment of the sera was omitted. All prevaccination and postvaccination sera were tested for non-specific haemagglutinins using African green monkey red blood cells. Sera containing such haemagglutinins were adsorbed with Cercopithecus erythrocytes.
In the serum-neutralization test, FL tissue cultures were used. Neutralization of the " wild " Edmonston strain (30-150 TCID50) was carried out for 2 hours at 27°C and the serum-virus mixtures were inoculated in 0.4-ml amounts into two culture tubes containing 1.6 ml of fresh M150 medium (Morgan, Campbell & Morton, 1955) plus 2% calf serum. The inoculated tube cultures (kept stationary) were incubated at 37°C, and serum titres were calculated from the 12th-day reading by Kiirber's method (Karber, 1931 (8-9) (8-10) (8-13) (7-11) (7-10) (7-9) (8-13) (9-12) (7-12) vaccine contained no live virus, consequently the incidence of fever in this group was similar to that of the control group. The means of the maximum temperatures taken 1-6 days after vaccination indicate that the vaccines did not produce fever during the first 6 days in any of the groups. However, fever appeared on the 7th-8th day and persisted for 1-5 days in the vaccinated groups. The means of the maximum temperatures taken 7-14 days after vaccination and the mean duration of fever in days were the lowest in the group that had received the Schwarz vaccine. Additional clinical symptoms observed in infants 7-14 days after vaccination are summarized in Table 2 . The frequency of rash was approximately the same in the three groups receiving live virus vaccines, with the exception of the group of children aged 8-12 months given Enders Edmonston B alone, which showed an incidence of 50 %. The mean onset of rash varied from 9.5 to 11.3 days in these groups. The rash appeared to be much milder than the rash associated with natural measles, with a limited distribution on the face, neck and trunk. None of the children showed Koplik's spots. Other symptoms, such as cough, coryza and conjunctivitis, appeared with about equal frequency in all five groups. Enders Edmonston B vaccine (alone) produced a somewhat higher incidence of mild pharyngitis (without follicular tonsillitis) than the Schwarz vaccine. The administration of gamma-globulin greatly reduced the incidence of pharyngitis.
Convulsions were observed in only one child, who had been vaccinated with Enders Edmonston B
vaccine. This 14-month-old boy developed a fever of 103.4°F (39.6°C) on the 8th day after vaccination and his temperature rose to 105lF (40.5°C) the The frequency of fever in the four groups is shown in Table 4 . The highest incidence of fever (103°F (39.5°C) and over) occurred again in the Enders Edmonston B group. The incidence of high fever was approximately the same in the group receiving Schwarz vaccine and the group given Enders Edmonston B vaccine plus gamma-globulin. Infants less than 12 months old showed higher pyrexial responses than those older than 12 months. This difference was not seen in the spring trial. The means of maximum temperatures taken 7-14 days after vaccination in each group were similar to the mean temperatures observed in the corresponding groups during the spring trial.
The incidence of rash in each group of the fall trial was significantly lower than that observed at the spring trial (Table 5 ). Other symptoms, such as cough, coryza and conjunctivitis, revealed only insignificant differences between control and vaccinated groups. The administration of gammaglobulin reduced the incidence of pharyngitis to about the same level as that noted in the control group.
Antibody response to the vaccines
Each vaccinated group showed a serological conversion rate of 100I% (Table 6 ). However, serum-neutralization titres of 2 1: 32 were observed in a smaller proportion of children at the fall trial than at the spring trial.
Vaccination of 6-month-old infants with Schwarz vaccine
In the fall trial an additional group of 29 6-monthold infants was inoculated with the Schwarz vaccine. The prevaccination sera of these children were tested for measles antibodies using the HI and serum-neutralization tests. Antibodies were revealed in 4 sera by the HI test and in 6 sera by the neutralization test. However, when the remaining 23 prevaccination sera were retested by the neutralization test using a very small dose of virus (3-10 TCID50), 5 additional sera were found to contain antibodies to measles virus. Thus, 11 of 29 infants appeared to have maternal antibodies at the time of vaccination. (7-11) (7-9) (8-12) (7-11) (7-11) (7-10) (7-14) (10-13) The clinical symptoms observed in 28 of these infants are summarized in Table 7 . One infant left the orphanage 10 days after vaccination but returned at the end of the trial for his postvaccination blood sample. In order to compare the results obtained in this group with those obtained in infants aged 7-12 months who had been vaccinated with the same vaccine, the clinical symptoms of the latter group and those of the control group (Tables 4 and 5 ) are also included in Table 7 . The frequency of high fever (103°F (39.5°C) and over) following vaccination was about the same in the infants aged 6 months as in those aged 7-12 months having no prevaccination antibodies. However, 70 % of the 6-month-old infants with maternal antibodies showed a fever of 101°F-102.9.F (38.3°C-39.4°C) 7-14 days after vaccination. It may be assumed that the fever was due to the vaccination, since only 20.8% of the placebo group showed fever over 101°F (38.3°C) and only a very few children with slightly elevated temperatures were found in any of the groups during the first week after vaccination (see Table 7 ). The onset of fever was delayed in the 6-month-old group with maternal antibodies.
The antibody response to Schwarz vaccine in the 6-month-old infants is compared with that in the infants aged 7-12 months in Table 8 . Ofthe 11 infants having prevaccination antibodies to measles virus, 8 showed no change in serum antibody titre one month after vaccination, while 3 showed no antibodies after vaccination, although all three had prevaccination antibodies. This is probably due to the normal decline of maternal antibodies in the second 6 months of life.
Of the 18 6-month-old infants without maternal antibodies, 17 showed an antibody response to the vaccine (94.4% conversion rate). Only 16.6% of this group had a good antibody response (serum neutralization titre 2 1: 32) as compared with 66.7% of the group aged 7-12 months. This may have been due to the presence of low-level maternal antibodies in these infants not detectable by the tests employed in this study. (1962) reported in the preliminary tests of his vaccine that high fever (103°F and over) occurred in 5.7 % of the vaccinated children. This figure varied from 2.5o% (Andelman et al., 1963) to 4.6% (Morley et al., 1964) and to 11.2% (Schwarz, 1964) in later studies. Krugman et al. (1963) found that, using the Schwarz vaccine, the percentage incidence of high fever in infants between 1 1/2 and 2 years of age was 35%/6-a rate significantly higher than the 15 % febrile reaction rate observed in older children. An analysis of the pyrexial responses included in Tables 1 and 4 reveals that 5.6 % and 25 % of infants less than 12 months old and 23.8% and 10.5% of infants older than 12 months showed febrile reactions in the spring and fall trials, respectively. The cause (Morley et al., 1964; Schwarz, 1964 II n'y eut guere de differences quant la fr6quence et la gravite des autres reactions (toux, coryza, conjonctivite, diarrhee) en fonction des diverses preparations vaccinales utilisees.
